braz j infect dis 2 0 1 7;2 1(2):162–170
http://dx.doi.org/10.1016/j.bjid.2016.11.006
1413-8670/© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
“It has never been more urgent for us to come together to end HIV and tuberculosis. We achieve the most when we work together, using all of our strengths, harnessing all of our collective potential to end HIV and tuberculosis for a healthier world as part of the Sustainable Development Goals.” ...Michel Sisibé, Executive Director of UNAIDS
more
13280–13285 / PNAS / September 9, 2008 / vol. 105 / no. 36
The aim of this handbook is to provide network members and other laboratories involved in the diagnosis of tuberculosis, with an agreed list of key diagnostic methods and their protocols in various areas of TB diagnosis, ranging from microbiological diagnosis of active TB to the diagnosis of latent ...TB infection. This handbook offers a single source of reference by compiling all methods, with a strong focus on standard (reference) and evidence-based methods. In so doing, it will also contribute to the improvement of disease surveillance data for Europe.
more
PeerJ PrePrints , http://dx.doi.org/10.7287/peerj.preprints.579v1 2 Nov 2014
This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from
this meeting
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij...ing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection. Full details are provided in this WHO policy statement.
more
The results of the SHINE trial have been published in the NEJM today. SHINE looked at whether treatment for children with minimal TB could be reduced from 6 months to 4 months. It found that the four month treatment was as good as the standard six months treatment for children with minimal TB
Copenhagen, Denmark, 24–25 August 2017
How to do it best for the patient and the family